News Articles
Latest articles, insights, and updates from the blog.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Ketamine Compounding Regulations in 2026: What Has Changed
An overview of the latest regulatory developments affecting compounded ketamine in 2026, including FDA enforcement updates, state-level changes, and the impact on patient access.
DEA Telehealth Prescribing Rules: What Changed in 2025
DEA telehealth prescribing rules for controlled substances in 2025: Ryan Haight extensions, in-person visit triggers, and what they mean for ketamine access.
Ketamine Clinic Safety Standards: What Patients Should Expect
An overview of emerging safety standards for ketamine treatment clinics, including clinical protocols, monitoring requirements, provider qualifications, and what patients should look for when evaluating a ketamine provider.
Compounding Pharmacies and Ketamine: What Patients Should Know
What patients should know about compounding pharmacies that prepare ketamine formulations, including quality standards, regulatory oversight, and how to choose a pharmacy.
State-Level Ketamine Therapy Regulations: 2025 Landscape
State-by-state ketamine therapy rules for 2025: telehealth prescribing, in-person visit triggers, supervision, and compounding limits — what changed and where.
The Rise of At-Home Ketamine Treatment Companies
Major at-home ketamine therapy companies compared by dose, monitoring, published outcomes, and pricing — and the safety questions to ask before you enroll.
Key Ketamine Research Developments in 2025
Ketamine research highlights from 2025: TRD trials, BPL-003 phase 2a, measurement-based care data, telehealth outcomes, and what shifted in clinical practice.
Ketamine Insurance Coverage: 2025 Trends and Developments
Ketamine insurance coverage in 2025: Spravato payer trends, off-label IV claim outcomes, prior-auth patterns, and what coverage gaps patients still face.
FDA Esketamine (Spravato) Updates
A summary of the latest FDA regulatory actions, label updates, and clinical developments related to esketamine (Spravato) for depression treatment.
Telehealth Ketamine: Evolving Regulations
Telehealth ketamine prescribing rules in 2025: DEA Ryan Haight extensions, in-person visit triggers, dose limits, and the state variations patients hit.